The application of human serum albumin in liver cirrhosis and its complications
- VernacularTitle:人血白蛋白在肝硬化及其并发症中的应用
- Author:
Yaxin LI
1
;
Huiguo DING
1
Author Information
- Publication Type:Journal Article
- Keywords: Albumins; Liver Cirrhosis; Ascites; Hepatorenal Syndrome; Hepatic Encephalopathy; Therapeutics
- From: Journal of Clinical Hepatology 2025;41(3):409-414
- CountryChina
- Language:Chinese
- Abstract: Albumin is synthesized in the liver， and in case of severe liver injury， albumin synthesis is reduced with structural alterations （such as an increase in methylation and glycosylation）， leading to a significant reduction in effective albumin in circulation. Albumin not only maintains plasma oncotic pressure， but also has the functions of antioxidation， anti-inflammation， immunomodulation， and transport. Current guidelines recommend the short-term application of human serum albumin in the treatment of large-volume paracentesis， hepatorenal syndrome， and spontaneous bacterial peritonitis in patients with liver cirrhosis， as it is shown that human serum albumin can help to reduce mortality. In addition， human serum albumin may improve the prognosis of cirrhotic patients with hyponatremia， non-SBP infections， and hepatic encephalopathy. However， there are still controversies over the application of human serum albumin in liver cirrhosis and related complications in terms of optimal dose and long-term efficacy.
